All In Biotech

Drug Trial Radar · NCT03682601

Sexual Penetration Pain in Postmenopausal Women: A Topical Botanical Drug Treatment

Sinecatechins Ointment, a Botanical Drug Derived From Green Tea, for the Treatment of Significant to Severe Secondary Provoked Vestibulodynia in Sexually Active, Post-Menopausal Women With Vulvovaginal Atrophy

Last checked: Nov 19, 2026Latest source record: Jul 27, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

32

Actual

Start

Aug 30, 2018

Primary completion

Feb 12, 2021

Study completion Feb 13, 2021

Sponsor

Lead sponsor
GTO Pharmaceutical, LLCAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 24, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 20 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will evaluate the use of topical 5 or 10% sinecatechins, a botanical drug derived from green tea for the alleviation of sexual pain in the area around the vaginal opening (the vulvar vestibule), that is a main source of pain during sexual contact or dyspareunia, in postmenopausal women, with vulvovaginal atrophy. Women may or may not be using estrogens. Half of the women will receive the study drug, 5 or 10% sinecatechins and half will receive placebo. In addition to the reduction or elimination of pain upon penetration, women may also experience increase in lubrication, arousal and intensity of orgasm

Conditions

  • Sexual Pain Disorders
  • Postmenopausal Symptoms
  • Vulvovaginal Atrophy
  • Female Sexual Dysfunction
  • Dyspareunia
  • Vulvodynia
  • Vestibulodynia
  • Arousal Disorders, Sexual
  • Genito-Pelvic Pain/Penetration Disorder
  • Female Sexual Arousal Disorder

Interventions

  • 5% sinecatechins ointmentDrug

    Topical 5% sinecatechins ointment will be applied once daily.

  • PlaceboDrug

    Aquaphor/vehicle

  • 10% sinecatechins ointmentDrug

    Topical 10% sinecatechins ointment will be applied three times per week up to once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Numerical Rating Scale for PainTime frame: Numerical Rating Scale for pain was assessed at Visit 1 (initial visit); Visit 2 (at 2 weeks), and Visit 3 (at 4 weeks).

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Lila Nachtigall, M.D.

    New York, New York

  • Miriam Greene, M.D.

    New York, New York

  • Cynthia Krause, M.D.

    New York, New York

  • Janis Enzenbacher, M.D.

    Nyack, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.